-
Product Insights
Pancreatic Diseases – Drugs In Development, 2023
Global Markets Direct’s, ‘Pancreatic Diseases - Drugs In Development, 2023’, provides an overview of the Pancreatic Diseases pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pancreatic Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Colitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Colitis - Drugs In Development, 2023’, provides an overview of the Colitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Gastroparesis – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroparesis - Drugs In Development, 2023’, provides an overview of the Gastroparesis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Proctitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Proctitis - Drugs In Development, 2023’, provides an overview of the Proctitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Proctitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niclosamide in Proctitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Niclosamide in Proctitis Drug Details: Niclosamide is under development for the treatment of ulcerative colitis,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Epcoritamab in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Epcoritamab in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Epcoritamab in Follicular Lymphoma Drug Details: Epcoritamab-Bysp (Epkinly) is a monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WP-1303 in Multiple Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WP-1303 in Multiple Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. WP-1303 in Multiple Sclerosis Drug Details: WP-1303 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niclosamide in Ulcerative Colitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Niclosamide in Ulcerative Colitis Drug Details:Niclosamide is under development for the treatment of ulcerative colitis, proctitis...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belatacept in Lung Transplant Rejection
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Belatacept in Lung Transplant Rejection Drug Details:Belatacept (Nulojix) is a soluble fusion protein consisting of a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Adrulipase alfa in Exocrine Pancreatic Insufficiency
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adrulipase alfa in Exocrine Pancreatic Insufficiency report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Adrulipase alfa in Exocrine Pancreatic InsufficiencyDrug Details:Adrulipase alfa is under development...